8-K: ENvue Medical Amends Incentive Plan, Adds Israeli Tax Compliance

ENvue Medical, Inc. has amended its 2024 Long-Term Incentive Plan to incorporate Israeli tax law compliance and reflect recent corporate updates.

Summary

• The Board of Directors of ENvue Medical, Inc. approved an amendment and restatement of its 2024 Long Term Incentive Plan on December 24, 2025.
• The Amended and Restated Plan updates the definition of "Awards" to include restricted stock units and other awards under Section 102 for Israeli law purposes, ensuring compliance with Israeli tax laws and requirements.
• Non-material updates include reflecting the company's name change from NanoVibronix, Inc. to ENvue Medical, Inc. and incorporating changes from the First Amendment approved by stockholders on December 4, 2025.
• The plan aims to attract and retain key employees, contractors, and outside directors by providing a proprietary interest in the company.
• A maximum of 1,205,454 shares of common stock are available for awards, with 100% potentially delivered as Incentive Stock Options.
• Outside Directors are limited to awards not exceeding $700,000 in Fair Market Value per calendar year, with an additional $700,000 for newly appointed directors.
• The plan includes provisions for various award types such as Stock Options, Restricted Stock, SARs, Restricted Stock Units, and Performance Awards, with specific rules for vesting, exercise, and treatment during corporate events.
• Awards granted to Israeli residents are subject to an Israeli Appendix, requiring Approved 102 Awards to be held in trust by an ITA-approved Trustee for a Restricted Period and imposing specific conditions on exercise and settlement to comply with Section 102 of the Israeli Tax Ordinance.

Sentiment

Score: 6

Explanation: The filing is a neutral, administrative update to an existing incentive plan, reflecting good corporate governance and compliance with international tax laws. It doesn't contain new financial performance data or significant strategic shifts, but the continued commitment to an incentive plan is generally positive for talent retention.

Positives

• The plan aims to attract and retain key talent by offering a proprietary interest in the company, which can align employee and shareholder interests.
• Compliance with Israeli tax laws for awards granted to Israeli residents ensures legal and tax efficiency for a segment of the workforce.
• The ability to reuse forfeited or expired shares for new awards optimizes the utilization of the authorized share pool.

Risks

• The plan's effectiveness in attracting and retaining talent depends on the perceived value of the awards and the company's performance.
• Changes in tax laws or regulations, particularly those related to Section 102 of the Israeli Tax Ordinance, could impact the tax treatment and attractiveness of awards for Israeli participants.
• The potential for dilution exists if a significant number of shares are issued under the plan, although the maximum number of shares is specified.
• The company's clawback policy allows for recoupment of awards in the event of financial restatements, which could affect participant compensation.

Future Outlook

The Amended and Restated 2024 Long-Term Incentive Plan is designed to continue attracting and retaining key talent, aligning their interests with the company's long-term welfare and performance. The plan's structure, including compliance with international tax regulations, supports the company's global operational strategy.

Management Comments

• The purpose of the Plan is to attract and retain the services of key Employees, key Contractors, and Outside Directors of the Company and its Subsidiaries and to provide such persons with a proprietary interest in the Company.
• The Plan and all transactions under the Plan are intended to comply with all applicable conditions of Rule 16b-3 promulgated under the Exchange Act.

Industry Context

This amendment is a standard corporate governance action for publicly traded companies, ensuring their equity compensation plans remain compliant with evolving regulatory landscapes, including international tax laws. The inclusion of specific provisions for Israeli tax compliance suggests ENvue Medical, Inc. has a significant operational or employee presence in Israel, a common practice for global medical technology firms. Such plans are crucial for competitive talent acquisition and retention in the highly specialized medical device and biotechnology sectors.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for minor dilution from new share issuance under the plan, but also benefit from improved employee retention and alignment of interests. The plan's compliance updates reduce regulatory risk.
• Employees/Contractors/Outside Directors: Direct impact through eligibility for equity awards, providing a proprietary interest in the company and an incentive for continued service. Israeli participants benefit from tax-compliant award structures.

Next Steps

• The Amended and Restated Plan will govern new awards granted after December 24, 2025.
• The company will continue to reserve and keep available the necessary shares of Common Stock to satisfy plan requirements.
• The Administrator (Board or Committee) will continue to designate eligible participants and grant awards under the updated terms.
• For Israeli Approved 102 Awards, the plan requires approval by the Israeli Tax Authorities (ITA) and awards must be held in trust by an ITA-approved Trustee.

Key Dates

Recommendation

This filing is an administrative update to an existing long-term incentive plan, primarily focused on regulatory compliance and minor corporate identity changes. It does not contain information that would fundamentally alter the company's financial outlook or strategic direction. While a well-structured incentive plan is positive for talent retention, this specific amendment is not a catalyst for significant share price movement, thus a 'hold' recommendation is appropriate for existing investors.

Keywords

ENvue Medical, NanoVibronix, Long-Term Incentive Plan, Equity Compensation, Stock Options, Restricted Stock Units, SEC Filing, 8-K, Corporate Governance, Employee Retention, Israeli Tax Law, Section 102, Executive Compensation